Thymosin Alpha-1 (Tα1) is a synthetic version of a naturally occurring peptide fragment derived from thymosin fraction 5, a protein found in the thymus gland. It has become an exciting subject of preclinical and laboratory research for its potential role in immune modulation, antiviral studies, and cancer-related models. While not approved for therapeutic use in many countries, Thymosin Alpha-1 continues to attract strong interest as a peptide of high relevance to immunology research.

Area of Interest

Research into Thymosin Alpha-1 has focused on several areas:

• Immune Modulation: Studied for its ability to enhance T-cell activity and influence immune system responses in laboratory models.
• Antiviral Research: Investigated in models of viral infection for its potential to modulate host defense mechanisms.
• Cancer Research: Preclinical studies have examined its possible roles in tumor suppression and improving immune surveillance.
• Adjunctive Applications: Explored as part of combination approaches in experimental immunotherapy settings.

These diverse areas of study reflect the broad scientific interest in Thymosin Alpha-1 as a promising candidate in laboratory-based immune system research.

Technical Information

• Chemical Name: Thymosin Alpha-1
• Synonyms: Tα1, Thymalfasin
• Molecular Formula: C₁₂₉H₂₁₅N₃₃O₅₅
• Molecular Weight: ~3108 g/mol
• Sequence (Amino Acid): Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
• CAS Number: 62304-98-7
• Peptide Classification: Synthetic peptide derived from thymosin fraction 5

Storage Guidelines

• Lyophilized peptide is stable at room temperature for short periods.
• For long-term storage, keep at −20 °C or below.
• Once reconstituted, store at 2–8 °C. Effective use period may vary depending on the solution used.

Solubility

Thymosin Alpha-1 is soluble in sterile water or aqueous buffers depending on purity and formulation.

References

• Goldstein, A. L., & Badamchian, M. (2004). “Thymosin alpha 1: biological activities, applications and potential.” Nature Reviews Drug Discovery, 3(7), 557–567. https://doi.org/10.1038/nrd1419
• Garaci, E., et al. (1995). “Thymosin alpha 1 in immune regulation and cancer.” Annals of the New York Academy of Sciences, 685, 363–380. https://doi.org/10.1111/j.1749-6632.1993.tb35806.x
• King, R., et al. (2002). “Thymosin alpha 1: past clinical experience and future potential.” International Immunopharmacology, 2(3), 283–291. https://doi.org/10.1016/S1567-5769(01)00187-3

Certificate of Analysis (COA): Available here